Hepatitis B Serology|
Within scope of accreditation
5-10% of healthy adults will not recover from acute hepatitis B infection and will develop chronic Hepatitis B infection. This percentage increases the younger the patient. Determining the Hepatitis B status using all markers such as HBeAg will ensure the patient can be treated with antiviral drugs and monitored for response and/or disease progression. HBsAb is used to indicate immunity post immunisation.
PURPOSE OF PROGRAMME:
To provide EQA for laboratories determining infectious status with HBV
PROGRAMME OF ANALYSIS:
Results are entered online via the UK NEQAS secure website. The distribution is open for three weeks. Intended results are usually uploaded the day after closing date. Late results are not accepted after intended results are uploaded.
Qualitative detection, consensus. General descriptive statistics.
PERSISTENT POOR PERFORMANCE:
See the Annual Directory for UK and Irish participants only
The first distribution of UK NEQAS for Microbiology was sent out by the then Public Health Laboratory Services on the 1st of May 1971 organised by Dr Peter Crone. This distribution consisted of one scheme, three bacteriology specimens, sent to 67 laboratories in the UK. One of our recent distributions consisted of 12 different schemes, comprising 8 bacteriology, 13 serology, 10 molecular and 9 mycology specimens, and sent to 53 countries representing over 1300 laboratories. UK NEQAS for Microbiology, operated by Public Health England, is a UKAS accredited proficiency testing provider No. 4715.